Gain Therapeutics Inc — Liquidità (NASDAQ:GANX) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Flusso di cassa derivante dalle attività operative -12.37 M-14.69 M-18.87 M-18.87 M-18.47 M -18.47 M Flussi di cassa derivanti dalle attività di investimento -94.21 K-14.77 M10.22 M4.98 M4.98 M — Liquidità derivante dalle attività di finanziamento 41.77 M-78.77 K12.64 M13.01 M28.45 M 28.45 M Liquidità libera -12.46 M-14.81 M-18.88 M-18.9 M-18.49 M -18.47 M

Notizie

H.C. Wainwright conferma il rating Buy su Gain Therapeutics

Gain Therapeutics presenta dati sui biomarcatori dallo studio sul Parkinson

Gain Therapeutics riporta riduzione dell’81% in biomarcatore del Parkinson

Gain Therapeutics reports 81% reduction in Parkinson’s biomarker

Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - BioAtla (NASDAQ:BCAB), ChowChow Cloud Internatio (AMEX:CHOW)

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why

Roth/MKM alza il target di prezzo delle azioni Gain Therapeutics a $10

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14%

Is Enhabit, Inc. (EHAB) Stock Outpacing Its Medical Peers This Year?

Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy

H.C. Wainwright conferma il rating Buy su Gain Therapeutics prima dei dati clinici

H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock ahead of trial data